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Abstract
Background
Mouse models for treatment of late-stage prostate cancer are valuable tools, but assessing the
extent of growth of the prostate and particularly its regression due to therapeutic intervention or
castration is difficult due to the location, small size and interdigitated anatomy of the prostate gland
in situ. Temporal monitoring of mouse prostate regression requires multiple animals and
examination of histological sections.
Methods: Initially, T2-weighted magnetic resonance imaging (MRI) was performed on normal year-
old C57/BL6 mice. Individual mice were repeatedly imaged using inhalation anesthesia to establish
the reproducibility of the method and to follow hormone manipulation of the prostate volume.
Subsequently, MRI fat signal was suppressed using a chemical shift-selective (CHESS) pulse to avoid
signal contamination and enhance discrimination of the prostate.
Results: High field (7T) MRI provides high resolution (117 × 117 µm in plane), highly reproducible
images of the normal mouse prostate. Despite long imaging times, animals can be imaged repeatedly
to establish reliability of volume measurements. Prostate volume declines following castration and
subsequently returns to normal with androgen administration in the same animal. CHESS imaging
allowed discrimination of both the margins of the prostate and the dorsal-lateral lobes of the
prostate (DLP) from the ventral lobes (VP). Castration results in a 40% reduction in the volume of
the DLP and a 75% reduction in the volume of the VP.
Conclusion: MRI assessment of the volume of the mouse prostate is precise and reproducible.
MRI improves volumetric determination of the extent of regression and monitoring of the same
mouse over time during the course of treatment is possible. Since assessing groups of animals at
each time point is avoided, this improves the accuracy of the measurement of any manipulation
effect and reduces the number of animals required.
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Background
Androgens regulate the growth of both normal and neo-
plastic prostate. Thus, for almost fifty years the principal
treatment for advanced stage prostate cancer has been
androgen ablation therapy by orchiectomy or, more
recently, pharmacological treatment with anti-androgens
or gonadotropin inhibitors. While most such prostate
cancers initially regress, they eventually become inde-
pendent of androgens for growth and metastasize fatally.
Mouse models of prostate cancer may prove very useful in
dissecting the signaling pathways important for both pro-
gression to cancer and inhibition of tumor cell growth [1].
As in humans, androgens promote mitosis and differenti-
ation of rodent prostate ductal epithelium, and further,
appear to inhibit apoptosis of differentiated cells [2]. After
androgen ablation, the balance between mitosis and
apoptosis is disrupted, and the prostate undergoes a wave
of cell death, involuting the gland [3]. However, in mice,
assessing prostate regression due to therapeutic interven-
tion or castration is difficult due to the intra-abdominal
location, small size and interdigitated anatomy of the
gland [4].
MRI of mouse prostate allows longitudinal assessment of
volume changes in an individual prostate over time. To
maximize utility, MRI should have very high resolution,
since the mouse prostate is only 20 mm3, and should
allow successive monitoring of the same mouse. Xu et al.
[5] successfully imaged a cohort of xenograft-bearing mice
on two separate occasions using a commercial 1.5T instru-
ment, but the resulting resolution was only 0.39 mm3.
Hsu et al [6] followed tumor development in TRAMP mice
with up to four imaging sessions in a 7T MRI with a reso-
lution of 0.175 mm3. Other investigators imaged the
TRAMP mouse prostate in situ on a single occasion at
higher resolutions [7]. The effect of chemopreventive
drugs on the volume of the TRAMP mouse prostate was
assessed at a single post-manipulation time point by MRI
[8,9]. The effect of castration on tumor volume in TRAMP
mice was monitored in the same mouse up to four times
over many months [10] but again the resolution was only
0.175 mm3. Instead of assessing tumor volume, a single 2-
D image was used to assess cross-sectional area of pros-
tates developing cancer in the absence of the tumor sup-
pressor genes PTEN and p53 [11]. Fricke, et al. [12]
recently reported using a 7T MRI 3-D imaging procedure
to measure prostate volume in normal and knock-out ani-
mals at a high resolution (0.005 mm3) and suggest that
longitudinal studies would be possible.
Our goals in this study are to improve the reproducibility,
precision, and resolution of mouse prostate volume deter-
mination by MRI. Additionally, by developing a tech-
nique to allow survival of the mouse, and hence imaging
the same animal over time during hormone level manip-
ulations, we will be able to greatly reduce the number of




All procedures were approved by the UC Irvine committee
on animal care. Male C57/BL6 mice (retired breeders
more than 1 yr old) were purchased from the NCI or
Charles River Labs. Mice were housed individually in the
UCI animal facility and all procedures were in accordance
with institutional guidelines. Animals were anesthetized
with Xylazine (13 mg/kg) and Ketamine (87 mg/kg), and
castrated via scrotal incision. Each testicle, vas deferens
and accompanying fat pad were removed and the blood
vessels and vas deferens ligated. The incision was closed
with surgical silk rather than wound clips for compatibil-
ity with MRI. Androgen was replaced using 5 mg/kg
5alpha-androstan-17beta-ol-3-one (dihydrotestosterone,
DHT, Sigma) in corn oil injected sub-cutaneously daily.
There was neither weight gain nor loss greater than 10%
for any animal during these manipulations. For imaging,
mice were anesthetized as above, and positioned inside
the instrument. Anesthesia was maintained using 1% iso-
flurane, 99% oxygen delivered via a nose cone for the
duration of the imaging.
MRI
Animals were placed on a removable stage, insulated for
warmth and held in position by wrapping in paper towel
and plastic wrap. They were then positioned inside a
shielded 8-leg highpass birdcage coil (65 mm diameter),
constructed in-house, which was used for RF pulse trans-
mission and signal reception. Experiments were per-
formed on a MRRS (MR Research Systems Ltd., Surrey,
UK) console interfaced to a 7T Oxford 300/150 horizontal
bore magnet with an inner bore size of 150 mm (Oxford
Instruments Limited. UK). The system is equipped with an
actively shielded gradient coil (Model BFG-150/90-S, Res-
onance Research Inc, Billerica, MA) with a maximum gra-
dient strength of 750 mT/m, 100 µs rise time and inner
diameter of 90 mm. The gradients are driven by Techron
series 7700 linear gradient amplifiers, with a maximum
slew rate of 150 T/m/s.
In pilot studies, T1- and T2-weighted images were used to
determine the optimal parameters for imaging the mouse
prostate  in vivo (data not shown, DNS). T2-weighted
images were superior due to less fat interference. The echo
time of the T2-weighted images also affected image qual-
ity, with 20 msec differentiating prostate best from the
surrounding tissue (DNS). Maintaining anesthesia using
injectables (Xylazine/Ketamine) proved difficult due to
decreased respiration and body temperature, and so a
combination of initial anesthesia with injectables Keta-
mine/Xylazine and maintenance anesthesia using isoflu-
rane/oxygen inhalation inside the magnet gave 90–100%
survival, depending on the imaging session duration.BMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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Longer total anesthesia time increased the incidence of
respiratory failure and death, which we need to avoid in
order to image the same animal over multiple sessions.
Using the final, optimized anesthesia paradigm, we were
able to collect data by averaging 8 image sets which gave
an adequate image signal to noise ratio and which
allowed limiting the imaging time to 2.5 h (3.5 h includ-
ing initial imaging to position the mouse and shim the
magnet) resulting in 100% survival from the anesthesia
and hypothermia due to the magnet. We successfully
imaged the same mouse up to 3 times over a period of 14
days to assess normal prostate volume determination
reproducibility, and subsequently imaged the same
mouse up to 8 times over a period of 40 days (b7m1) and
10 times over 37 days (b5m2) to follow castration-
induced regression and DHT-induced re-growth of the
prostate. Finally, images were collected from two test mice
and the identification of each organ on the MRI was con-
firmed by gross examination (DNS). A total of 21 mice
were used in these studies. Four mice were not imaged,
eight mice were imaged on a single occasion, while nine
mice were imaged on multiple occasions.
For our initial studies, scout proton spin-echo images in
the axial orientation (TR/TE = 1080 ms/23 ms, 25 slices,
slice thickness = 0.5 mm, image matrix size = 128 × 128
FOV = 35 mm2), were used to accurately localize the posi-
tion of the mouse prostate. Then a 2-D interleaved multi-
echo spin-echo sequence (TR/TE = 4500 msec/20 ms, 32
slices, slice thickness = 0.3 mm with no separation, image
matrix size = 256 × 256, field of view (FOV) = 30 × 30
mm, NEX = 8 averages) was used to produce images for
volume determination.
Subsequently, imaging was performed with a chemical
suppression sequence (CHESS) to repress the signal from
the abdominal fat. After scout images were obtained, spec-
troscopy identified the resonant frequency of the lipid-
derived protons (typically 950–1000 Hz). A Gaussian 240
Hz pulse was used for CHESS fat suppression using the
lipid resonance frequency and a pulse duration of 1000
µs. A 2-D interleaved CHESS spin-echo with fat suppres-
sion sequence (TR/TE = 4500 msec/25 ms, 32 slices, slice
thickness = 0.2 mm with no separation, image matrix size
= 256 × 256, FOV = 30 × 30 mm, NEX = 8 averages) was
used to acquire the fat-suppressed images of mouse pros-
tate.
Volume determination
Each series of 32 image slices was analyzed using NIH
ImageJ [13]. These were assembled as a stack and the cir-
cumference of the whole prostate was outlined on each
slice (typically 10–20 slices total) containing identifiable
prostate (illustrated in Figure 1, panels A1', A2' and A3'),
and the number of bounded pixels in each slice was com-
puted. The number of pixels in each bounded slice was
added and multiplied by the voxel size, 0.0041 mm3, to
yield the prostate volume. Voxel size is the volume of one
pixel in the MRI. It is the image resolution, 117 × 117 µm
(computed by dividing the FOV, 30 mm2, by the number
of points in the image matrix, 256 × 256) and multiplied
by the slice thickness. The voxel size for the initial (non-
CHESS) studies was 0.0041 mm3, and for the subsequent
CHESS images it is 0.0027 mm3. Volumes were deter-
mined by a single segmenter at least twice for each image
session and agreed within 5%, or they were redetermined.
For the initial studies, multiple images were captured of
most mice before treatment (normals), and the mean vol-
umes and accompanying standard error of the means are
presented. In the reproducibility study, the coefficient(s)
of variation (CV) was calculated as the appropriate SD
divided by the mean and expressed as a percentage.
Results
Imaging of the normal prostate
Prostate volumes were measured in mature mice. Figure 1
(Panels A1–A3) shows prostate image slices from one
mouse (batch 3, mouse 3 (b3m3)) obtained on three sep-
arate days over an eight day span. Panels A1–A3 show the
slice with the largest cross-sectional area of the prostate
from each session. The circumference of the whole pros-
tate was outlined on each slice (typically 10–20 slices
total) containing identifiable prostate (illustrated in Fig-
ure 1, Panels A1'-A3'). The number of pixels in each
bounded slice was added and multiplied by the voxel size,
0.0041 mm3, to yield the prostate volume (22.14 +/- 1.02
mm3 (mean +/- SE, n = 3) for mouse b3m3). Other nor-
mal mature mice show similar prostate size (Figure 1,
panels B', C', and D'). The average volume from 7 individ-
ual mature mouse prostates, is 23.80 +/- 2.62 mm3 (mean
+/- SD, n = 7) in year old mice, where the individual val-
ues are illustrated in Figure 1E. To assess the reproducibil-
ity of the measurements over multiple imaging sessions,
the coefficient of variation was determined for individual
animals to range from 1.7% to 10.9%, and overall was
6.5% for the five mice imaged multiple times (80% CI
upper bound = 13.6%). We find the volume of the whole
prostate varies between individual mice, but that one
imaging session is sufficient to determine baseline pros-
tate volume for the subsequent studies.
Imaging regression of the prostate following castration
Three mice from Figure 1 were castrated following MRI
assessment of normal prostate volume, and reduction of
the prostate volume was assessed by MRI over 11 days.
Figure 2 shows the prostate image of maximum cross-sec-
tional area for imaging sessions performed on mouse
b2m3 one (A), three (B), eight (C), and ten (D) days after
castration. The total volume of the prostates from three
separate mice declined ~75% following castration (Figure
2E), to 6.04 mm3 +/- 1.05 mm3 (mean +/- SD, n = 3).
Figure 2 also illustrates two problems. Fat surrounding the
prostate gland produces an intense signal which appearsBMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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MRI of prostate following castration Figure 2
MRI of prostate following castration. Mouse b2m3. A: 1 day; 
B: 3 days; C: 8 days; and D: 10 days. The second column (A'-
D') shows the prostate outlined in white as in Figure 1. E: 
Regression of the prostates of three individual mice. Square 
symbols represent the volume of the prostate of b2m3, cir-
cles represent b5m1, and triangles represent b5m2.
MRI of normal mouse prostate Figure 1
MRI of normal mouse prostate. Prostates from year old C57/
BL6 mice were imaged (FOV = 35 mm2, 256 × 256 pixels). A: 
Images of b3m3 on three different days (A1, A2, A3). B: 
b3m2, C: b4m1, D: b2m3. Second column (A1'-D') shows 
the prostate outlined in white. Each image is the central 8.75 
mm square (64 × 64 pixels) portion of the complete MRI 
image. F: Plot of prostate volumes for the indicated mice, in 
cubic millimeters. Error bars represent standard error of the 
mean of the prostate volume for each animal that was imaged 
multiple times (b2m3, b3m2, and b3m3 were imaged 3 times, 
b5m1 and b5m2 were imaged twice and b4m1 and b4m2 
were imaged once).BMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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to 'shift' into the prostate and, as the prostate regresses, its
composition (of water, fat and prostatic fluid, or other
constituents) changes over time, reducing the signal to
noise ratio, thus hampering our ability to differentiate the
prostate from surrounding tissues in the MR images.
Optimizing MRI by CHESS reveals prostate lobes
The MRI signal shift due to fat is illustrated in Figure 3.
The white arrow in panel A indicates a region of fat signal
shift of several millimeters, within the muscle. The intense
fat signal shift, down and to the left, leaves a dark area, up
and to the right, corresponding to the region vacated by
the shifting fat signal. In the magnified image (panel A')
of the central portion of Figure 3, the left black arrow
points to a void resulting from the fat signal shift, and the
right arrow to a hyperintense region where the fat signal
has shifted into the prostate. This fat signal complicates
the drawing of the border of the prostate as some estima-
tion of the underlying margin is required.
Fat signal can be greatly reduced by selectively suppressing
fat protons prior to acquiring the water proton signal,
using a chemical shift selective imaging sequence
(CHESS). The frequency of fat proton emission is deter-
mined during pilot imaging, and a pre-saturation pulse is
applied prior to slice image acquisition. Figure 3B shows
an image slice of normal prostate acquired using CHESS.
The intense abdominal fat (labeled F in Figure 3A') and
other fat signals have been eliminated, and the prostate
borders are well delineated (Figure 3B'), greatly facilitat-
ing precise quantitation. An unexpected but very valuable
result of the CHESS imaging is the greater signal intensity
in the ventral lobe relative to the dorsal-lateral region (Fig-
ure 3B', VP versus DLP). This may be due to higher the
water content of the prostatic fluid in the more numerous
secretory ducts of the ventral lobe.
We used CHESS imaging to determine the volume of nor-
mal mouse prostate lobes. At the same time, we were able
to increase the accuracy of our volumetric determinations
by reducing the slice thickness to 200 µm, resulting in a
voxel size of 0.0027 mm3. The solid bars in Figure 3C
show the volumes of the VPs derived from four normal
mice (solid bars; 19.04 +/- 2.78 mm3, mean +/- SD, n = 4).
The grey bars show the DLPs, whose average volume is
12.39 +/- 1.29 mm3 (mean +/- SD, n = 4) from four nor-
mal mice. Although Figure 1 demonstrates good repro-
ducibility and inter-animal agreement for total prostate
volume, comparison with the CHESS images shows that
standard T2 MRI underestimates total (VP + DLP) prostate
volume (23.80 versus 31.43 mm3).
Regression and re-growth of individual lobes of the mouse 
prostate
The ventral lobe of the mouse prostate regresses more
than the dorsal or lateral lobes (which are difficult to dis-
tinguish from each other in the mouse). Figure 4 shows a
time course (similar to Figure 2) of mouse prostate CHESS
images following castration (panels A-D). Panels A'-D'
show the same slices with the ventral prostate outlined in
white and the dorsal-lateral in black. CHESS imaging
greatly enhances the signal to noise ratio in the images at
the later time-points and the elimination of the fat signal
CHESS suppresses fat signal artifact and facilitates discrimina- tion between ventral and dorsal-lateral lobes Figure 3
CHESS suppresses fat signal artifact and facilitates discrimina-
tion between ventral and dorsal-lateral lobes. A: T2- 
weighted MRI. A': Magnification of the central 64 × 64 pixel 
square, indicated by the white box in A. White arrow in A 
and black arrows in A' illustrate the shift of the signal derived 
from fat. The locations of the prostate (P), ureter (U) and 
abdominal fat (F) are indicated. B: T2-weighted image 
acquired using CHESS. B': Magnification as in A'. White 
arrows indicate ventral prostate (VP) and dorsal-lateral pros-
tate (DLP). C: Volume of the VP (solid bars) and DLP (grey 
bars) of normal mice determined using CHESS images, as in 
Figure 1F.BMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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overlap allows more accurate delineation of the lobe
boundaries. The volume of the ventral prostate is reduced
71.67 +/- 0.07% (mean +/- SD, n = 3) over 10 days (Figure
4E), while the the dorsal-lateral prostate regresses only
33.78 +/- 8.43% (mean +/- SD, n = 3, Figure 4F). Thus,
MRI demonstrates that prostate lobe-specific reductions
in mouse are similar to rat.
The prostate of a castrated animal returns to pre-castrate
size, and indeed larger, following androgen supplementa-
tion. Two weeks following castration, mice were given
daily DHT injections and the prostates repeatedly imaged.
Figure 5 shows re-growth over a two week period (panels
A-F). The dorsal-lateral lobes (panels A'-F', black outlin-
ing) return to pre-castration volume by 9 days of treat-
ment and then growth arrests (Figure 5G, squares). In
contrast, the ventral lobe (white outline) returns to pre-
castration volume by 9 days, but then increases further for
the duration of the treatment (Figure 5G, circles).
Discussion
We applied MR imaging to precisely quantitate the vol-
ume of the mouse prostate in vivo over multiple imaging
sessions to follow regression and re-growth. This method
should also be useful to follow tumor development and
drug treatment effects in prostate and other organs. We
have optimized the MRI technology protocol in a variety
of ways to significantly improve on previous applications
of MRI to prostate imaging in the mouse. Specifically, we
refined the anesthesia administration protocol to allow
imaging of a mouse for 3.5 hours. Extended imaging time
is necessary to produce the highest quality images, by pro-
viding sufficient time to position the prostate at the focal
point of the field, shim the magnetic field, and capture 8
averages of the image, enhancing image quality by
improving the signal to noise ratio. We used a 256 × 256
matrix, a small (30 mm2) FOV, and very thin (200 µm)
non-interleaved slices to obtain the smallest voxel size
reported for mouse prostate imaging. Our protocol pre-
cisely determined the volume of the normal prostate from
a single MRI session, as evidenced by the observation that
volumes determined from additional imaging sessions
did not vary significantly. Although developed independ-
ently, our method yields prostate volumes similar to those
reported in MRI studies by Fricke, et al. [12], while our
two-fold smaller voxel size due to a smaller coil and
longer imaging times served to maximize the resolution
and allow more precise volume determination. In rats, the
wet weight of the ventral lobe is reduced 75% within 10
days of castration, while the dorsal and lateral lobes are
only reduced 50% [14]. In this study, MRI revealed a 75%
castration-induced volume loss for the whole prostate
(Figure 2). Further, use of CHESS fat suppression to differ-
entiate the lobes reveals 72% VP reduction and 39% DLP
reduction (Figure 4). While direct comparison of the MR
MR-CHESS imaging of prostate involution Figure 4
MR-CHESS imaging of prostate involution. Prostate of b6m1 
following castration A: 1 day; B: 3 days; C: 8 days; D: 10 
days. Second column (A'-D') shows the VP outlined in white 
and the DLP outlined in black. Each image is the central 7.5 
mm square (64 × 64 pixels) portion of the complete MRI 
image (FOV = 30 mm2, 256 × 256 pixels). E: Plot of volume 
during regression of the VPs of two individual mice. F: Plot of 
volume during regression of the DLPs of two individual mice. 
Triangle symbols represent the volume of the prostate of 
b5m3 and circles represent the volume of b6m1.BMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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images to histological images at timed intervals following
manipulation are a "gold standard" for accurate determi-
nation of prostate volume, using CHESS to optimize dif-
ferentiation of prostate from surrounding tissue allows
confidence in determining the organ boundaries used in
prostate volume determination. Using MR to produce
images of the same animal over time increases precision
of the volume measurements due to elimination of inter-
animal variation. Only five animals were needed to pro-
duce reliable data in the regression and re-growth studies,
whereas a minimum of 4 animals/time point at 10 time
points, 40 animals total, would be required to produce
similar data histologically.
Mice deficient in genes regulating apoptosis have helped
identify regulators of cancer development and progres-
sion in the rodent prostate [4]. Similarly, understanding
the genetic basis of androgen withdrawal induced regres-
sion provides insight into androgen-independent progres-
sion of prostate cancer. Rat prostate lobes are large and
can therefore be much more readily physically dissected
from surrounding tissues. Regression can be monitored by
sacrificing the rats, recovering the prostate and weighing
individual lobes. Physical separation also allows measure-
ment of protein content, DNA content, and nucleosomal
fragmentation due to apoptosis. Two weeks following cas-
tration, the DLP mass declines 50% and VP declines 75%
[14]. Unfortunately, rats are not yet a genetically tractable
system and measuring apoptosis and regression in mouse
prostate is technically challenging.
Since physical isolation of the lobes of mouse prostate is
much more difficult than the rat [15], most investigators
forego dissection and measuring regression and instead
use histological techniques to measure apoptosis in the
prostate. Pyknotic or TUNEL-labeled cells increase in the
rat prostate following castration, but differences between
castrated and normal are small (5 versus 30 per 100 acini)
[16] such that many sections must be examined for accu-
rate assessment. Moreover, pyknotic and TUNEL-stained
cells are transient [17]. For these reasons, studies examin-
ing castration-induced regression of the mouse prostate
have yielded contradictory results for some important sig-
naling pathways, particularly Fas. To measure the effects
of Fas deletion on androgen withdrawal induced regres-
sion of the prostate, both the organ size and rate of apop-
tosis have been measured in Fas-deficient (lpr) mice. Two
studies sacrificed groups of animals at intervals following
castration, microdissected and weighed the prostates.
Since accurate microdissection of an interdigitated 20
mm3 organ is technically challenging, it is perhaps not
surprising that these groups reported contradictory results
[18,19]. Two reports also measured the incidence of apop-
totic cells by either histological characteristics [19] or
TUNEL staining [20] in castrated Fas deficient mice and
MR-CHESS imaging of prostate re-growth during androgen  supplementation of castrated mice Figure 5
MR-CHESS imaging of prostate re-growth during androgen 
supplementation of castrated mice. Prostate from b7m1 fol-
lowing castration and DHT treatment. A: day 0 (16 days fol-
lowing castration); B: 2 days DHT treatment; C: 4 days DHT 
treatment; D: 9 days DHT treatment; E: 12 days DHT treat-
ment; F: 16 days DHT treatment. Second column (A'-F') as 
in Figure 4. G: Plot of prostate volume during re-growth of 
the ventral prostates of two individual mice. Triangle symbols 
represent the volume of the prostate of b5m2, circles repre-
sent the volume of the VP of b7m1 and squares represent 
the volume of the DLP of b7m1.BMC Urology 2007, 7:12 http://www.biomedcentral.com/1471-2490/7/12
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report no difference between deficient and normal mice.
However, small differences in apoptotic or proliferation
rate accumulate over time to yield measurable changes in
prostate volume [3]. Thus, use of the MR imaging tech-
niques described in this report, which integrate these
small changes in the same animal, might provide a more
accurate method to revisit the role of Fas in androgen
withdrawal induced apoptosis and the resulting prostate
regression.
Conclusion
We have optimized very high resolution imaging of the
mouse prostate in living animals. Our examination of the
castration induced regression of the normal mouse pros-
tate demonstrate that we can track the reduction in total
prostate volume (Figure 2) and that using CHESS to sup-
press fat signal, we were able to further discriminate the
ventral from the dorsal and lateral lobes of the prostate,
and monitor volume changes in each individually (Figure
4). This additional level of anatomic discrimination
should be useful in monitoring lobe-specific tumor
growth in mice. We were also able to monitor prostate re-
growth following administration of exogenous androgens
(Figure 5). This MRI technique is sufficiently sensitive to
detect even small changes in the size of the mouse pros-
tate since monitoring of one animal repeatedly over time
is more accurate than measuring the mean of a group of
animals sacrificed at intervals after castration or other
treatment. An added benefit is to dramatically reduce the
number of animals needed to measure the effect of any
given manipulation.
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